Results 21 to 30 of about 12,220 (249)

Dipeptidyl-Peptidase IV inhibitors and glycemic control in type 2 Diabetes Mellitus

Journal of College of Medical Sciences-Nepal, 2016
Background & Objectives: Type 2 diabetes mellitus (T2DM) is a progressive disease, characterized by insulin resistance, impaired glucose-induced insulin secretion, inappropriately elevated glucagon concentrations, and hyperglycemia.
Lokendra Bahadur Sapkota, Sangita Thapa
doaj   +1 more source

Dipeptidyl peptidase IV inhibitors derived from a mangrove flora Rhizophora mucronata: An in silico approach

Bangladesh Journal of Pharmacology, 2012
Dipeptidyl peptidase IV (DPP IV) is responsible for conversion of glucose tolerance (GLP-1), into inactive form. The inhibition of DPP IV would be beneficial in the treatment of diabetes mellitus.
Selvaraj Gurudeeban, Kaliyamurthi Satyavani, Thirugnanasambandam Ramanathan, Palanisamy Ravikumar   +3 more
doaj   +1 more source

DPP-IV Inhibitory Potentials of Flavonol Glycosides Isolated from the Seeds of Lens culinaris: In Vitro and Molecular Docking Analyses

Molecules, 2018
Dipeptidyl peptidase IV (DPP-IV), a new target for the treatment of type 2 diabetes mellitus, degrades incretins such as glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide. DPP-IV inhibitors shorten the inactivation of GLP-1,
Bo-Ram Kim, Hyo Young Kim, Inhee Choi, Jin-Baek Kim, Chang Hyun Jin, Ah-Reum Han   +5 more
doaj   +1 more source

Characterization of Novel Dipeptidyl Peptidase-IV Inhibitory Peptides from Soft-Shelled Turtle Yolk Hydrolysate Using Orthogonal Bioassay-Guided Fractionations Coupled with In Vitro and In Silico Study

Pharmaceuticals, 2020
Five novel peptides (LPLF, WLQL, LPSW, VPGLAL, and LVGLPL) bearing dipeptidyl peptidase IV (DPP-IV) inhibitory activities were identified from the gastrointestinal enzymatic hydrolysate of soft-shelled turtle yolk (SSTY) proteins.
Nhung Thi Phuong Nong, Yu-Kuo Chen, Wen-Ling Shih, Jue-Liang Hsu   +3 more
doaj   +1 more source

Identification of novel human dipeptidyl peptidase-IV inhibitors of natural origin (Part II): in silico prediction in antidiabetic extracts. [PDF]

PLoS ONE, 2012
BACKGROUND: Natural extracts play an important role in traditional medicines for the treatment of diabetes mellitus and are also an essential resource for new drug discovery.
Laura Guasch, Esther Sala, María José Ojeda, Cristina Valls, Cinta Bladé, Miquel Mulero, Mayte Blay, Anna Ardévol, Santiago Garcia-Vallvé, Gerard Pujadas   +9 more
doaj   +1 more source

Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection

Pharmaceuticals, 2021
The current outbreak of severe acute respiratory distress syndrome (SARS) or nCOVID-19 pandemic, caused by the coronavirus-2 (CoV-2), continues to wreak havoc globally.
Praveen P. N. Rao, Amy Trinh Pham, Arash Shakeri, Amna El Shatshat, Yusheng Zhao, Rahul C. Karuturi, Ahmed A. Hefny   +6 more
doaj   +1 more source

Synthetic Approaches to Novel DPP-IV Inhibitors—A Literature Review

Molecules
Dipeptidyl peptidase IV (DPP-IV) is a serine protease whose inhibition has been an object of considerable interest in the context of developing novel treatments for type 2 diabetes mellitus.
Valentin Petrov, Teodora Aleksandrova, Aleksandar Pashev   +2 more
doaj   +1 more source

Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus [PDF]

Diabetes & Metabolism Journal, 2016
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral antidiabetic agent for the treatment of type 2 diabetes mellitus. They increase endogenous levels of incretin hormones, which stimulate glucose-dependent insulin secretion, decrease ...
Sung-Ho Kim, Jung-Hwa Yoo, Woo Je Lee, Cheol-Young Park   +3 more
doaj   +1 more source

Metabolic Syndrome-Preventive Peptides Derived from Milk Proteins and Their Presence in Cheeses: A Review

Applied Sciences, 2020
The metabolic syndrome (MetS) is defined as the occurrence of diet-related diseases such as abdominal obesity, atherogenic dyslipidemia, hyperglycemia (insulin resistance) and hypertension.
Anna Iwaniak, Damir Mogut
doaj   +1 more source

The Antidiabetic Potential of Alpha‐Mangostin: A Review of Preclinical and Clinical Evidence

AgriFood: Journal of Agricultural Products for Food, EarlyView.
Alpha‐mangostin is a compound from the pericarp of Garcinia mangostana. The antidiabetic effects of alpha‐mangostin include enhancing insulin secretion, improving glucose uptake through GLUT receptor upregulation, reducing oxidative stress and inflammation, promoting wound healing, reducing HbA1C, reducing HOMA‐IR index, and decreased mRNA expressions ...
Oliver Dean John, Nur Damia Iwani Zulkiflee, Siti Raihanah Shafie, Ramlah George, Melonney Patrick   +4 more
wiley   +1 more source